Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $66.94M.
ENTERPRISE VALUE (EV)
$66.94M
Coya Therapeutics, Inc.
Market Cap
$113.77M
Enterprise Value (EV)
$66.94M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Coya Therapeutics, Inc. (COYA) | $113.77M | $66.94M |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $114.24M | $41.06M |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | $108.94M |
| Genelux Corporation (GNLX)vs › | $116.59M | $109.82M |
| Foghorn Therapeutics Inc. (FHTX)vs › | $117.43M | $92.45M |
| Immunic, Inc. (IMUX)vs › | $109.93M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.02M | $118.49M |
| Apyx Medical Corporation (APYX)vs › | $109.49M | $121.50M |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $118.50M | $103.37M |
| BGM Group Ltd. (BGM)vs › | $118.63M | $108.28M |
Market Cap
$113.77M
Total Debt
$0.00
Cash
$46.82M
Enterprise Value
$66.94M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
